Peptides AcademyPeptides for Metabolic Health
Metabolic peptides overlap heavily with fat-loss peptides but emphasize different endpoints: insulin sensitivity, visceral adiposity, lipid panels, and HbA1c. GLP-1s, GIP/GLP-1 agonists, and tesamorelin dominate the evidence.
How peptide Targets Peptides for Metabolic Optimization
For broad metabolic improvement — insulin sensitivity, glycemic control, lipid panel, visceral adipose reduction — the evidence dominant class is GLP-1 and dual GIP/GLP-1 agonists. Semaglutide improves HbA1c by 1.5-2.0 points and reduces cardiovascular events (SELECT). Tirzepatide improves HbA1c further and produces larger weight-driven metabolic improvements. Tesamorelin specifically reduces visceral adipose tissue by 15-20% and improves lipid fractions.
Secondary metabolic peptides include MOTS-c (mitokine, insulin sensitivity in preclinical models) and 5-Amino-1MQ (small-molecule NNMT inhibitor with preclinical metabolic data). Both lack robust human outcome data.
The metabolic peptide protocol has largely converged on GLP-1 class agents because of the magnitude of effect and the growing cardiovascular outcome evidence. Peptides without that evidence base remain secondary or experimental.
Recommended Peptides (7)
5-Amino-1MQ
Research-Grade
A small-molecule NNMT inhibitor (technically not a peptide) grouped with peptides in fat-loss contexts, investigated in preclinical obesity and muscle-aging models.
Liraglutide
Saxenda / Victoza
The first GLP-1 receptor agonist approved for chronic weight management (Saxenda, 2014) — an acylated human GLP-1 analog with ~13-hour half-life dosed once daily.
MOTS-c
Research-Grade
A 16-amino-acid peptide encoded in the mitochondrial 12S rRNA — investigated as a metabolic regulator of AMPK signaling and insulin sensitivity.
Retatrutide
Eli Lilly (investigational)
An investigational triple GIP / GLP-1 / glucagon receptor agonist from Eli Lilly, showing the largest weight-loss effect sizes yet reported in obesity trials (up to ~24% at 48 weeks in phase-2).
Semaglutide
Ozempic / Wegovy / Rybelsus
Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.
Tesamorelin
Egrifta
FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.
Tirzepatide
Mounjaro / Zepbound
First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.
Frequently Asked Questions
Semaglutide or tirzepatide for metabolic optimization?
Where does MOTS-c fit?
Other peptide Skin Concerns
Peptides for Anti-Aging
Anti-aging is the loosest indication in the peptide literature. 'Longevity' claims are typically ove…
Peptides for Cognitive Function
The cognitive peptide space is dominated by Russian-developed compounds (Semax, Selank, Cerebrolysin…
Peptides for Fat Loss
The peptide conversation around fat loss has shifted entirely since the GLP-1 era. This page separat…
Peptides for Hair Growth
The peptide hair-growth literature is dominated by GHK-Cu topical and copper peptide complexes. Sign…
Peptides for Injury Recovery
The regenerative peptide category — BPC-157, TB-500, GHK-Cu — has more preclinical signal than most …
Peptides for Longevity
Longevity peptides carry the most hype-to-evidence gap in the field. Russian bioregulator peptides (…
Peptides for Muscle Growth
Hypertrophy-focused peptide protocols cluster around two axes: GH-axis amplification and direct anab…
Peptides for Skin & Glow
Cosmetic peptides have decades of dermatology research. GHK-Cu, Matrixyl, Argireline, and polynucleo…
Peptides for Sleep
The peptide-for-sleep conversation is thinner than marketing implies. DSIP is the only dedicated sle…